Articles tagged with Heart Failure
A study published in JAMA Cardiology found that blacks with atrial fibrillation have nearly double the risk of adverse outcomes compared to whites. The study analyzed data from the Atherosclerosis Risk in Communities (ARIC) Study and found significant racial differences in outcomes related to AFib.
Researchers at George Washington University are studying a potential new treatment for heart failure by restoring parasympathetic activity to the heart, which could improve cardiac function. The study uses high-speed optical assessments of heart function to identify heart-specific benefits of oxytocin nerve activation.
A UCLA-led study estimates that nearly 28,500 deaths in the US could be prevented annually through use of a new FDA-approved class of cardiovascular medication. The therapy helps reduce mortality in patients diagnosed with heart failure and reduced ejection fraction by enhancing protective hormonal systems.
A recent study published in the European Heart Journal found that teenage body weight is a significant predictor of heart failure risk in adulthood. Men with a BMI of 20 or higher had a significantly increased risk of heart failure, with the risk rising steeply with increasing body weight.
Research of over 1.6 million Swedish men reveals that being overweight as a teenager significantly increases the risk of heart failure in early middle age. The study found a nearly ten-fold increased risk for those with a BMI of 35 or more, emphasizing the importance of maintaining a healthy weight from an early age.
A global study found that patients with type 2 diabetes admitted to the hospital for congestive heart failure face a high risk of mortality, highlighting the need for increased attention to this critical condition. The study suggests that heart failure outcomes should receive equal scrutiny as other cardiovascular events in future rese...
A study found that a biomarker linked to increased cardiovascular risk is associated with a higher risk of heart disease, heart failure, and death. The study suggests that measuring the biomarker twice over time can provide better risk characterization.
The new guidelines call for population-based approaches to prevent cardiovascular disease, with adapted target levels for blood pressure and lipids. Reducing population risk by 1% can prevent 25,000 CVD cases and save €40 million per year.
A recent study published by the European Society of Cardiology found that nearly 25,000 patients developed heart failure within four years of their first heart attack. The risk factors for this condition include older age, socioeconomic deprivation, and comorbidities such as diabetes.
A new study published by the European Society of Cardiology found that flu vaccination reduces hospitalization risk for heart failure patients. The research analyzed over 60,000 patient records and found a 30% lower risk of cardiovascular hospitalization after vaccination.
A subgroup analysis from the ATMOSPHERE trial found that aliskiren was not superior or non-inferior to standard treatment with an ACE inhibitor in heart failure patients with diabetes. In those with diabetes, aliskiren was associated with a lower risk of symptomatic hypotension but did not demonstrate better cardiovascular outcomes.
A study of over 20,000 patients with heart failure found that flu vaccination was associated with a 35% lower risk of developing dementia. Those who received the flu vaccine more than three times had a 55% lower risk. The researchers suggest that vaccination may reduce inflammation and prevent brain damage
A study of over 4,000 heart failure patients found that exercise was associated with an 18% lower risk of all-cause mortality and an 11% reduced risk of hospitalization. Exercise benefits were consistent across all patient characteristics, including severity, age, and gender.
A study of nearly 12,000 heart failure patients found that one year after hospitalization, 68% had returned to work, while 25% remained unemployed. Younger patients, those with higher education levels, and men were more likely to return to work.
The new guidelines provide evidence-based recommendations for the diagnosis and treatment of acute and chronic heart failure, including the use of LCZ696 and adaptive servo-ventilation. The guidelines also introduce a new category for patients with mid-range ejection fractions and provide novel recommendations for preventing and treati...
CHF patients with predominant central sleep apnea (CSA) are at higher risk for death and unplanned hospitalization, particularly those in the most severe NYHA class. ASV therapy has been shown to be effective in treating CSA, but its impact on mortality rates remains unclear.
A simple screening test can accurately predict the severity of heart disease in patients with heart failure. The test calculates a patient's sarcopenia score based on their age, grip strength, and calf circumference, making it a useful evaluation method for daily clinical practice.
A new implantable VAD designed specifically for small children has shown encouraging results in a study using living sheep. The device, called the Infant Jarvik 2015, offers improved hemolysis profile and increased flow rate compared to its predecessor, paving the way for potential clinical trials.
New techniques and devices are being developed to treat heart failure, mitral valve regurgitation, and coronary artery lesions. Studies show high procedural success rates and improvements in heart function and quality of life.
Patients treated with processed autologous adipose-derived regenerative cells (ADRCs) demonstrated symptomatic improvement and reduced heart failure hospitalizations. The ATHENA trial results showed a trend towards lower rates of angina, despite no improvement in left ventricle ejection fraction (LVEF) or ventricular volumes.
Researchers have discovered a gene signature that characterizes the transition from dilated cardiomyopathy (DCM) to heart failure. The study found increased expression of fibrotic and inflammatory genes, as well as changes in heart muscle cell proliferation and metabolic profiles.
A new device enables real-time monitoring of central venous and pulmonary artery pressures in patients with single ventricle Fontan anatomy, reducing the risk of heart failure. The first implantable hemodynamic monitor has been successfully placed in two patients, showing early safety and feasibility.
Autologous cardiac cells, particularly atrial appendage-derived cells, show promise for gene and RNA therapies in heart failure. The review discusses financial and authority-based restrictions influencing research in this field, highlighting the potential of autologous tissues as cell therapy sources.
Myotonic dystrophy causes wasting of skeletal muscles and arrhythmia due to mutated RNA sequences that alter gene regulation. Researchers identify altered SCN5A splicing as key factor in cardiac dysfunctions, paving way for potential treatment restoration of normal heart function.
Researchers are exploring new treatments for heart failure using transplanted umbilical cord cells, activated endogenous cardiac stem cells, and immune therapy. A clinical trial assessing the safety of allogenic umbilical cord lining sub-epithelial cells is also underway.
A murine model has been developed to study the mechanisms of reverse cardiac remodeling, a process where the heart returns to its normal structure and function after injury. The model shows that normalization of left ventricle structure and function is accompanied by improved cardiac myocyte function and reduced expression of genes ass...
A study by researchers at the Heart Failure Center of the University of São Paulo suggests that wearing a respirator mask can lessen the impact of vehicle emissions on people with heart failure. The results also indicate that this type of mask can reduce the risk of developing cardiovascular disease for healthy individuals.
A phase 2 clinical trial shows significant benefits from stem cell therapy in patients with class III and IV heart failure. After 12 months, patients receiving the treatment had a lower rate of deaths, cardiovascular hospitalizations, and clinic visits for sudden worsening of heart failure symptoms compared to those receiving a placebo.
A new study finds that end-stage heart failure patients who received stem cell therapy experienced a 37 percent reduction in cardiac events, including deaths and hospital admissions. The treatment showed fewer side effects and complications compared to the placebo group.
The ATMOSPHERE trial found aliskiren alone or in combination with enalapril had no significant benefit on mortality and hospitalization rates in patients with heart failure. However, adding aliskiren increased the risk of symptoms like low blood pressure and elevated potassium levels.
A new device that monitors lung fluid accumulation reduces heart failure-related hospitalizations by over half and death rates by 39% compared to standard care. Patients who used the Edema Guard Monitor took medication earlier, preventing pulmonary congestion from reaching advanced stages.
Investigational stem cell therapy derived from a patient's own blood marrow significantly improved outcomes in patients with severe heart failure. The study found that the treatment reduced deaths by 37% and hospitalizations by 49% compared to placebo.
A daily dose of vitamin D3 improves heart function in people with chronic heart failure, improving ejection fraction from 26% to 34%. The study, known as VINDICATE, involved over 160 patients and found that taking vitamin D3 regularly may lessen the need for an implantable cardioverter defibrillator.
A new implantable medical device intended to stimulate the vagus nerve in heart failure patients did not significantly reduce hospitalization or death rates. However, it showed improvements in walking endurance and quality-of-life measures, with significant gains in distance walked and quality of life scores.
Researchers from the University of Pennsylvania found that heart transplants can be performed in adult patients with prior corrective surgery for congenital heart disease with excellent outcomes. The study, which included 17 consecutive patients, showed a 100% survival rate at both 30 days and one year.
A new meta-analysis reveals a clear correlation between higher BMI, waist circumference, and the risk of heart failure. Overweight individuals had a 35% increased risk of heart failure compared to normal weight individuals.
In a rat model of volume-overload-induced heart failure, LOX inhibition partially restored systolic and diastolic function while reducing cardiac fibrosis and interstitial myocardial collagen. LOX over-activation promotes progressive cardiac fibrosis and heart failure progression.
A study published in JAMA Cardiology found that intracoronary gene transfer increased left ventricular function beyond standard heart failure therapy. The treatment, which involves introducing a specific protein into heart cells, showed significant benefits in patients with nonischemic heart failure.
The Phase 2 clinical trial results indicate that AC6 gene transfer safely increased left ventricular peak -dP/dt and left ventricular ejection fraction in non-ischemic heart failure patients. Symptoms of heart failure were also reduced in participants treated with RT-100.
A study led by Dr. Roger J. Hajjar and Dr. Woo Jin Park found that CCN5 protein can reverse established cardiac fibrosis in heart failure models. The researchers used trichrome staining to show the reversal of cardiac fibrosis, demonstrating potential for new anti-cardiac fibrosis therapies.
A large-scale study examining the relationship between incretin-based drugs and hospitalization for heart failure found no increased risk. The study, conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), analyzed health records of over 1.4 million patients in Canada, the US, and the UK.
A new study has made significant progress toward a novel approach to convert scar tissue into healthy heart muscle, which could improve the quality of life for people with heart failure. By removing a barrier to conversion, researchers were able to significantly increase the yield of muscle-like cells.
Scientists at Gladstone Institutes discover a new type of cell that can organically develop into heart cells and replicate. The induced expandable cardiovascular progenitor cells (ieCPCs) significantly improved heart function in mice after a heart attack, offering a promising potential treatment for heart failure.
Temple researchers have uncovered a new mechanism by which aldosterone triggers heart damage, involving GRK2 and GRK5 signaling molecules. The study found that inhibiting these kinases could provide a potential therapeutic solution for heart failure.
Researchers at Cedars-Sinai Medical Center have made a breakthrough in treating heart failure with preserved ejection fraction, a difficult-to-treat condition affecting millions. Cardiosphere-derived cells (CDCs) infused into laboratory rats reversed the condition, improving heart function and filling capacity.
Researchers found a significant reduction in emergency department visits and hospitalizations for heart failure exacerbation after bariatric surgery. Patients who underwent the procedure experienced a 40% decrease in these events, suggesting substantial weight loss can help prevent heart-failure-related adverse events.
Researchers found that failing cardiac tissue had increased levels of acetylated mitochondrial proteins, promoting metabolic defects in heart failure. In a mouse model, they detected elevated protein acetylation at the earliest stages of heart failure, supporting the role of hyperacetylation in disease progression.
Research suggests that moderate alcohol consumption may be beneficial for cardiovascular health, with studies showing a lower risk of heart failure and acute myocardial infarction among frequent drinkers. However, high levels of alcohol consumption were associated with increased risks of other diseases and social problems.
The European Society of Cardiology has launched the first European advice on emergency care for patients with acute heart failure. The guidance highlights that mortality from acute heart failure is even higher than from a heart attack, and that care lags 30 years behind standard treatment pathways for heart attacks.
A Yale University study found VA hospitals to have slightly lower mortality rates among older men with specific conditions, but higher readmission rates compared to non-VA hospitals. The differences were small, indicating that the VA healthcare system is doing comparatively well for these vulnerable patient groups
Research from the University of Leicester found high levels of trimethylamine N-oxide in acute heart failure patients, a metabolite produced by gut bacteria breaking down L-carnitine from red meat. The study suggests a possible link between red meat consumption and increased risk of heart disease.
A new study has discovered a type of noncoding RNA called Chast that drives heart failure in mice and may promote cardiac hypertrophy. The researchers found that targeting this lncRNA with an antisense oligonucleotide could prevent and treat cardiac hypertrophy, improving heart function.
A daily dose of beetroot juice significantly improved exercise endurance by 24% after one week, while also reducing resting systolic blood pressure by 5-10mmHg. The study found that the juice's inorganic nitrate content has beneficial effects on vascular health and oxygen metabolism.
A recent study published in JAMA Internal Medicine found that remote telemonitoring did not significantly reduce all-cause 180-day hospital readmissions among heart failure patients. Despite this, the intervention group reported improved quality of life at 180-days compared to usual care patients.
Researchers have uncovered the molecular mechanism that regulates how the heart pumps blood, with titin protein identified as key player. The study's findings could lead to new medications more effectively treating heart failure.
Researchers from Sanford Burnham Prebys Medical Discovery Institute found that failing hearts switch to ketone metabolism as an alternative fuel source. This discovery may lead to new therapeutic targets to prevent or slow progression of heart failure.
A recent study published in the American Journal of Cardiology found that early diagnosis and treatment of sleep apnea may reduce six-month readmissions for patients hospitalized with heart failure. Researchers discovered a significant reduction in hospital visits among patients who used positive airway pressure therapy regularly.
Researchers at Osaka University have developed a therapeutic method using periostin1-specific neutralizing antibodies to inhibit the onset of cardiac failure in the chronic phase, improving patients' quality of life and reducing medical costs. The study's findings suggest that periostin1 is the primary cause of cardiac failure after AMI.
An irregular heartbeat is a stronger risk factor for stroke, heart disease, and death in women than in men. The cause is unclear, but the results support more aggressive treatment of risk factors in women.
New research finds that women with heart failure live longer and experience lower mortality rates when equipped with implanted defibrillators. The study used data from the Get With the Guidelines-Heart Failure registry to compare survival in patients with and without ICDs.